Expression of inflammatory interleukins and selected miRNAs in non-small cell lung cancer

Tumours are characterised by an ability to avoid immune destruction and the presence of cancer-associated inflammation. Better understanding of the link between lung cancer and such inflammation is vital for early detection and personalized treatment. Thus, we examined the mRNA expression of interleukins IL-1 beta, IL-6, IL-17 and miR-9, miR-122 as potential useful biomarkers of NSCLC. Tumour tissues, non-cancerous tissue and blood samples were collected from 39 patients with primary NSCLC undergoing surgical treatment. The selected RNA was isolated from tissue samples and selected miRNAs from peripheral blood exosomes. This RNA was transcribed to cDNA and quantified using RT-qPCR. Significantly higher expression of the selected interleukins was observed in non-cancerous than tumour tissue, and IL-6 was significantly higher in the tumour tissue of patients with a history of <= 40 pack-years (PYs) (2.197, IQR: 0.821-4.415) than in those with>40 PYs (0.461, IQR: 0.372-0.741; p=0.037). It is clear that inflammatory processes play a role in NSCLC, as indicated by the upregulation of IL-1 beta and IL-6 in tumour and adjacent tissue, and that smoking has a strong influence on inflammation in tumourigenesis, demonstrated by the upregulation of IL-6 in tumour samples among patients with <= 40 PYs compared to>40 PYs.

Automated summary

Tumours have the ability to avoid immune destruction and exhibit cancer-associated inflammation. The upregulation of interleukins IL-1 beta and IL-6 in non-small cell lung cancer (NSCLC) tissues suggests that inflammatory processes play a role in NSCLC, with a strong influence of smoking history on inflammation in tumourigenesis.